HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Malignant transformation of infantile hemangioma to angiosarcoma: response to chemotherapy with bevacizumab.

Abstract
We describe a child initially diagnosed with multi-focal infantile hemangioma (cutaneous, hepatic, pulmonary), a benign vascular lesion, which underwent malignant transformation to angiosarcoma. The use of anti-angiogenic agents, such as bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, has been reported in adults with angiosarcoma. Treatment with chemotherapy (gemcitabine and docetaxel) and bevacizumab resulted in disease response with progression free survival of 12 months. This report describes the response to chemotherapy and bevacizumab in a child with angiosarcoma and highlights the potential for malignant transformation of benign vascular lesions and the need for careful monitoring.
AuthorsMichael R Jeng, Beng Fuh, Julie Blatt, Anita Gupta, Arnold C Merrow, Adrienne Hammill, Denise Adams
JournalPediatric blood & cancer (Pediatr Blood Cancer) Vol. 61 Issue 11 Pg. 2115-7 (Nov 2014) ISSN: 1545-5017 [Electronic] United States
PMID24740626 (Publication Type: Case Reports, Journal Article)
Copyright© 2014 Wiley Periodicals, Inc.
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
Topics
  • Angiogenesis Inhibitors (therapeutic use)
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Bevacizumab
  • Cell Transformation, Neoplastic
  • Hemangioma (pathology)
  • Hemangiosarcoma (drug therapy, pathology)
  • Humans
  • Infant
  • Male
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: